To minimize donor risk and maintain public support, volunteer donor stem cell donation, whether by mobilized leukapheresis or marrow aspiration, requires careful donor eligibility assessment. Many contraindications to stem cell donation exist, yet analyses of donor deferral rates are not available. In a 36-month series encompassing 2493 potential stem cell donors, we analyzed frequencies and reasons for deferrals. All were presumed eligible by their registries because of previously submitted structured health questionnaire and formal telephone interviews. After assessment by our center's physicians, 3.3% of donors proved ineligible, but 5.6% more were eligible for only one of the collection methods. Higher deferral rates were associated with female sex, increasing age and mobilized stem cell donation vs marrow. Exclusion criteria were identified with approximately similar frequency by medical history, physical examination and laboratory testing. Reasons for deferrals almost exclusively served to protect donor safety; the rare recipient-directed safety concerns could be, and often were, overridden in agreement with the transplant center. As formal analyses have shown, with careful assessment, stem cell donation is acceptably safe, but the plethora of deferral reasons mandate that only physicians with specific experience should evaluate stem cell donors, that is, this task should not be delegated to paramedical personnel.
INTRODUCTION
Allogeneic hematopoietic SCT is a potentially curative treatment modality for an increasing spectrum of patients with malignant and non-malignant diseases. [1] [2] [3] Currently, more than 75% of allogeneic transplants originate from matched-unrelated donors. 3 Almost half of all unrelated stem cell grafts in the world are donated by German donors 4 who are organized in 28 independent donor registries. The great public support of volunteer stem cell donation builds on the overwhelmingly positive safety record of stem cell donation, [5] [6] [7] [8] [9] [10] as well as on the trust that specialized physicians who are independent of the stem cell registry and of the transplant center will carefully and individually evaluate potential stem cell donors. As the recent scandal surrounding solid organ transplant allocation in Germany has taught us, the public is very sensitive toward real and perceived infringements of their trust. 11 The gift of stem cells is entirely altruistic. It involves very relevant discomfort and time commitment, yet is without any tangible benefit for the donor except for 'warm glow'. 12 Clearly, therefore, donor safety is the prime responsibility of physicians caring for volunteer donors and supersedes the patient's need for stem cells for survival.
The situations for whole blood/blood component donation and stem cell donation are very different. For one, stem cell donation is relatively rare compared with whole blood donation. Thus in Germany, one thousand whole blood donations are performed for every stem cell donation. 4, 13 Second, the risks associated with stem cell donation-whether due to general anesthesia for BM aspiration or growth factor administration for PB stem cell apheresis-are much higher, as stem cell donation is markedly more invasive than whole blood donation. Even with careful donor evaluation, a serious adverse event frequency of 0.11-0.6% for PBSC and 0.043-1.34% for BM donation is reported, compared with a serious adverse event frequency of 0.005% for whole blood donation. 5, 8, [14] [15] [16] The relative uniqueness of certain HLA combinations implies that the directed donation from a designated stem cell donor may be a recipient's only chance of survival. Suitably matched mature blood cell components, on the other hand, are generally available in ample quantities. Evaluation of whole blood donors thus similarly follows stringent criteria for donor and recipient safety, yet in case of doubt donors are generously deferred as the product is relatively easily replaceable. Stem cell donor evaluation heeds donor and recipient safety in consideration of the relative uniqueness and vital criticality of the product for a specific recipient. In case of doubt, recipient-directed exclusion criteria can be overridden, in agreement with the TC. Both greater invasiveness and complication rates for the donor and the unique immediately vital relevance of the product for the patient imply a markedly more thorough and individual evaluation of stem cell donors compared with whole blood donors. In spite of the vital importance of the donation for the patient, donor safety is an absolute, intangible value, of which the evaluating physician in the donor center is the safeguard.
Ample systematic data are available regarding blood donor deferrals, 17, 18 while, except for a small cohort of family donors, similar analyses regarding stem cell donors are strikingly missing. 19 The primary aim of these studies was to allow transplant center physicians a preliminary estimate of the likelihood of receiving stem cells from a given donor with respect to age, sex and stem cell source. We here report on the formal assessment of frequencies and reasons for donor deferrals for donor-or recipient-directed contraindications in a cohort of 2493 successive individuals referred to our center over a period of 36 months (January 2009-December 2011), representing more than 5% of the world's matched-unrelated stem cell donor population for that period, for evaluation as unrelated stem cell donors.
DONORS AND METHODS
Stem cell donors and donor evaluation After matching for a specific patient in terms of histocompatibility and other criteria, volunteers registered in one of the contracting stem cell donor registries were referred to the Department for Cellular Therapeutics of the German Red Cross Blood Service Baden-Württemberg-Hesse Institute Frankfurt for stem cell donor evaluation and clearance. At that point in time, they had successfully passed a formal assessment by structured health survey (ZKRD health questionnaire or equivalent) and standardized telephone evaluation by medical or paramedical personnel from the registries, that is, only donors presumed eligible were referred. The request of the transplant centers for clearance generally specified a preferred stem cell source, PBSC or BM; occasionally, the non-preferred stem cell source was excluded as an alternative. Donor evaluation involved a complete medical history by a specifically trained physician, a full physical examination including assessment of venous status for apheresis collection, where indicated, imaging studies including, at the minimum, abdominal ultrasound and additional studies as indicated by history and examination, as well as a wide laboratory panel (see Table 1 ). All abnormal findings were individually assessed. Additional tests or medical specialty consults were ordered where indicated to make a definitive decision regarding donor clearance for the scheduled donation. If a definitive or suspected diagnosis was incompatible with stem cell donation from the point of view of donor safety, the donor was deferred for donation of one or both stem cell sources. In cases where a potentially increased risk of adverse effects due to the specific donation procedure was suspected, this was discussed with the donor, and the alternative form of stem cell donation was discussed, as well as availability of a potential alternative donor was considered. In contrast, diagnoses associated with a potential recipient risk were not necessarily considered a reason for donor deferral. Transplant centers could, and frequently did, request to proceed with a donor in spite of formal recipient-directed ineligibility. An exhaustive list of potential exclusion criteria cannot be provided, but recommendations of the WMDA were generally considered. 20 Although not all donor centers agree with this approach, a very strict interpretation of the WMDA recommendation to restrict central line use to 'exceptional circumstances' was adopted by us, that is, lack of suitable peripheral venous access was considered an exclusion criterion for PBSC apheresis. Other contraindications include but are not limited to any poorly compensated chronic medical condition, history of malignancy or autoimmune disease. Patients with spinal ailments, potential reasons for deferral for BM donation, could be cleared after positive evaluation by an orthopedic surgeon.
In the absence of a history of thromboembolic events, a heterozygous Factor V Leiden mutation was not considered a contraindication for mobilized stem cell donation, and accordingly, donors were not routinely genotyped. Given its frequency in the Caucasian population (3.8%), 21 we can extrapolate that almost one hundred donors with that mutation received G-CSF in our cohort alone, without any adverse effects, supporting our approach to this entity. Donors engaging in sexual behaviors considered exclusion criteria for whole blood donation were not automatically excluded as donors; with specific testing for blood transmissible STDs and consent from the TC, such donors could be cleared for stem cell donation. Contrary to recommendations, drug or alcohol abuse per se was also not an exclusion criterion, unless i.v. drug abuse was admitted or suspected. Moreover, major psychiatric illnesses not necessarily lead to donor deferral, unless the donation process was perceived as a donor risk for aggravation of the underlying illness. In two cases where physicians were not convinced of the donor's compliance with the donation process, prophylactic cryopreservation of the graft was performed with consent by donor and transplant center; both products were later used for their patients.
Analysis
All charts from all successive donor evaluations performed between January 2009 and December 2011 were reviewed to assess, even if at the time they had been evaluated only for donation of one of the alternative stem cell sources, whether they could also have been cleared for the alternative form based on our clinical procedures. Whenever a donor was deemed ineligible for one or both forms of stem cell donation, the reasons were documented. Gender, age, preferred, non-preferred and undesired (by donor or by transplant center) source of stem cells, as well as Hepatopathy of unknown origin (6); multiple rec. hepatic adenomas and obesity (1) OB/gynecologic (3)
Early pregnancy (2); Q. ovarian carcinoma (1) Hematologic (20) , hemostaseologic (4) Chronic/newly diagnosed isolated thrombocytopenia (4/3); significant etiologically unclear chronic eosinophilia (1); monoclonal gammopathy (3); Q. myeloproliferative disease (3); unexplained hyporegeneratory anemia (2); bilineage cytopenia (2); unexplained severe iron deficiency anemia (1); Q. cyclic neutropenia (1); dysfibrinogenemia (1); lupus anticoagulant (2); cardiolipin antibodies (1) Infectious (2) Acute Lyme disease (1); anti-HCV-IgG (IgM and NAT negative) (1) Pulmonary (3) Uncontrolled bronchial asthma (2); chronic-obstructive pulmonary disease and emphysema (1) Musculoskeletal (3) Acute symptomatic intervertebral disk prolapse (1); Q. muscular dystrophy (1); Q. Curshmann-Steinert muscular dystrophy (1) Nervous system incl. CNS (6) or psychiatric (4) Q./confirmed inflammatory CNS disease (2/3); Q. hereditary multisystem atrophy (1); depression with/without suicidal ideation (1/1), factitious hyperthyroidism (1); chronic anxiety disorder and chronic eating disorder (1) Urogenital, nephrologic (4) or metabolic (1) S. p. urothelial carcinoma (1); Q. renal carcinoma (1); unclear renal failure (1); florid glomerulonephritis (1); hypokalemic periodic paralysis (1) Unclassified (5) Splenomegaly and morbid obesity (1); unexplained lymphadenopathy (3); poor venous access and morbid obesity (1) Abbreviations: CNS = central nervous system; HCV = hepatitis C virus; NAT = nucleic acid amplification testing; TC = transplant center. Diagnoses leading to complete donor deferral for stem cell donation; potentially only temporary deferrals (to be reconsidered after additional clinical investigations, initiation of therapy or clinical observation) are printed in italics. In agreement with TC and donor registry, these donors were not further pursued. Psoriasis arthritis (2); S. p. juvenile oligoarthritis (1) Nervous system incl. CNS or psychiatric (1) Psychogenic dyskinesia (1) Urogenital, nephrologic or metabolic (9) Q. mild glomerulonephritis/IgA nephritis (8); S. p. Leydig cell tumor (1) Unclassified (26) Poor venous access (22) ; splenomegaly (2); familial systemic lupus (1); familial predisposition for hematologic malignancies (1) Abbreviations: CNS = central nervous system; β-HCG = β-subunit of hCG gonadotropin; OB = obstetrics; TC = transplant center. Diagnoses leading to donor deferral for PBSC, but not BM donation; potentially transient deferrals (to be reconsidered after additional clinical tests, medical/surgical treatment or extended clinical observation) are printed in italics. In individual agreement with TC and donor registry, these donors were not further pursued.
systems. Most frequent were dermatologic, endocrine and hematologic conditions (including coagulopathy), each being responsible for 410% of deferrals. Poor venous access caused 11% of the deferrals of PBSC donors; this was not an exclusion criterion for BM donation. Six to o 10% of deferrals were based on urogenital/renal or musculoskeletal conditions, ⩽ 5% of deferrals each were for cardiovascular, gastrointestinal, gynecologic, infectious, pulmonary or neurologic/psychiatric diagnoses. In most cases, deferrals were based on a single diagnosis. Tables 2, 3 and 4 summarize all individual diagnoses leading to donor deferral for one or both kinds of donation. Diagnoses made on imaging studies are shown in Table 5 . Although in principle transplantable to the recipient, autoimmune disease was not considered an exclusion criterion for stem cell donation per se, only for G-CSF mobilized PBSC donation, in the interest of donor safety. Many donors with a diagnosis of autoimmune disease went on to donate BM. Only two deferrals (2.5% of the complete deferrals) were for recipient-related conditions (history of Lyme disease, positive anti-HCV-IgG with negative NAT), where it was felt that donation would have been safe from the donor's perspective.
Donor deferral as a function of stem cell source, gender and age Deferral rates were significantly greater for mobilized PBSC donation (8.3% overall) than for BM donation (3.8% overall). Thus, in addition to the 82 complete deferrals, 119 donors were cleared for BM only but not for PBSC, whereas only 12 donors were cleared for PBSC but not BM. Seven donors not cleared for PBSC had a history of lower back problems requiring an orthopedic consult before a decision regarding clearance for BM donation. However, in these the consult was not sought because BM donation was not an option, either because they did not consent to BM donation or because the TC did not want BM, so that a definitive decision regarding clearance for BM donation was not made. This being an analysis of medical deferrals, the 17 and 268 cases, respectively, where donors refused consent to mobilized PBSC donation or BM donation, respectively, are also not considered 'deferrals', although these donors were obviously not cleared for donation of this type of stem cell source. The higher deferral rate for mobilized PBSC than for BM was mostly attributable to autoimmune disease, diagnosed in 84 (3.4%) of all donors and thus being by far the most prevalent diagnostic group for donor ineligibility. Autoimmune disease in most cases (exceptions: several cases of newly diagnosed autoimmune endocrinopathy with pathologic end hormone levels) led to deferrals only for mobilized PBSC donation but not for BM collection. Females were 50% more likely than men to be deferred from mobilized PBSC donation (8.3% overall, 10.9% in females and 7.2% in males), but not from BM donation (3.8% overall, 3.7% in females and 3.8% in males) (Figure 1a) . The trend held throughout the observed age range. Comparison of reasons/frequencies for deferrals identifies a threefold higher frequency of (subclinical) autoimmune conditions that were diagnosed in females, in agreement with the expected prevalence in a Caucasian population, 22 as well as a higher likelihood of inadequate peripheral venous access as leading differences. Obstetric/ gynecologic diagnoses, including pregnancies (n = 2), led to donor deferrals in only five cases and were thus not the foremost reasons for the higher deferral rate of females. The same trends held when data were reanalyzed based on the assumption that donors with inadequate peripheral venous access could have been cleared; the overall reduction in deferral rates for PBSC donation was approximately 10%, it applied mostly to females. With the exception of one morbidly obese donor, who was deferred from PBSC because of poor peripheral veins and from BM because of an increased risk from anesthesia; the (complete deferrals) rate was unaffected by this re-analysis (Figure 1b) .
Moreover, donor deferral rates were significantly associated with age for both stem cell sources (mobilized PBSC donation: P = 0.004; BM: P = 0.001) and sex for PBSC only (mobilized PBSC donation: P = 0.009; BM: P = 0.754; Figure 1 ). An abrupt increase in Table 4 . Diagnoses (frequencies) for donor deferrals from BM only by organ system (4) v. Willebrand-Jürgens syndrome (3); combined FVII+FX deficiency (1) Infectious (0) Pulmonary (0) Musculoskeletal (8) Diaphragmal hernia with thoracic stomach (1); symptomatic spondylolisthesis lumbar spine (1); Klippel-Feil syndrome (1); S.p. several spondylodeses lumbar spine (1); surgically treated scoliosis lumbar spine (2); S.p. NPP lumbar spine and residual paresthesias (1); rec. NPP lumbar spine (1) Nervous system incl. CNS or psychiatric (0) Urogenital, nephrologic or metabolic (0) unclassified (0) Abbreviations: CNS = central nervous system; NPP = neuropathic pain; TC = transplant center. Diagnoses leading to donor deferral for BM, but not PBSC donation; one potentially only temporary deferral (to be reconsidered after surgical closure) is printed in italics. In agreement with TC and donor registry, this donor was not further pursued. Table 5 . Diagnoses for donor deferrals made on abdominal ultrasound exam or chest X-ray
Imaging studies New diagnoses
Abdominal ultrasound exam Splenomegaly (3), adrenal incidentaloma (1), recurrent multiple hepatic adenomas (1), Q. ovarial carcinoma (1), Q. renal cell carcinoma (1) Chest X-ray Hemodynamically relevant atrial septum defect (1), diaphragmal hernia and thoracic stomach (1) Diagnoses made by routine imaging studies on presumably healthy donors.
Deferrals of stem cell donors S Bräuninger et al deferral rates for PBSC donation was observed in females beyond the age of 30 years, whereas a similar increase in males was not observed until two decades later. Higher deferral rates in older donors are not surprising, but our data for the first time provide formal evidence.
DISCUSSION
To account for the markedly greater invasiveness of stem cell donation compared with whole blood or blood component donation, a much more detailed and much more donor safetycentered approach to donor evaluation is being taken. While prediction of donor safety in blood donors is largely limited to exclusion of donors who, based on their history, may not be able to tolerate the volume loss (coronary heart disease, arterial hypotension, low body weight, etc.), the bulk of evaluation criteria pertain to product quality (anemia for whole blood donation, platelet count for thrombocyte apheresis) or product safety (sexual behavior, travel/infectious disease history, medical interventions potentially associated with bacteremia). Whole blood donor deferral rates in the order of magnitude of 12.8% (and 5% after exclusion of anemia as a reason for deferral) have been reported. 18 The overall greater probability of deferral of female stem cell donors, but pertaining only to PBSC donation, is largely attributable to their greater propensity for autoimmune disease. 22 As only presumably healthy donors were referred for assessment, the autoimmune diseases diagnosed during workup were largely subclinical, predominantly Hashimoto thyroiditis and other compensated thyroid conditions, and also some others such as Graves or Addison's disease and vitiligo; almost all were new diagnoses. The rationale for exclusion of individuals with autoimmune/inflammatory disease is provided by strong clinical evidence for (direct or indirect) activation of autoreactive T-cell clones and macrophages during G-CSF treatment, leading to potentially severe clinical aggravation of autoimmune and other inflammatory syndromes. 8, 20, [23] [24] [25] [26] [27] [28] A second more common reason for donor deferral in our hands, although not universally accepted, observed in almost 1% of all evaluated donors and also pertaining only to PBSC donation, was inadequate peripheral venous access. Like autoimmune disease, this was also observed more commonly in females than in males (1.7% vs 0.6% of all assessed females/males) and accounted for 11% of all deferrals for PBSC donation. Importantly, our data indicate that inversely, peripheral access is sufficient for PBSC collection in 499% (2470/2493) of donors, which clearly illustrates the lack of a rationale for routine central line placement in donors. Routine central line placement for healthy donor stem cell donation is discouraged by the WMDA. That recommendation was fueled by a recent death of a stem cell donor caused by pneumohematothorax after central line placement. 29, 30 A third not uncommon reason for donor loss (although not considered a deferral) was refusal of consent for BM donation in cases where contraindications against G-CSF-mediated stem cell mobilization precluded PBSC donation, BM harvest was considered safe by the assessing physician but non-preferred by the donor.
After correcting for autoimmune disease and poor peripheral access as causes for donor deferral, deferral rates for BM and PBSC donation were very similar. All other reasons for donor exclusion were sporadic, yet all decisions to defer donors were based on scientific reasoning or clearcut clinical precedents.
The observed several-fold higher likelihood of donor deferral in older donors, in addition to other considerations favoring younger donors (higher likelihood of severe GVHD, 31 possibly poorer stem cell yield 7, 32, 33 ), reinforces that selection of younger donors should be preferred. Inversely, if the best matched donor is an older female, the transplant center should prepare for a 10% likelihood of her not being able to proceed to donation.
The plethora of diagnoses made in presumably healthy donors involving diagnoses from virtually all medical specialties/organ systems underscores the necessity of evaluation of potential stem cell donors by physicians with thorough medical training and significant specific experience in the field of stem cell mobilization and procurement. As most of the deferral reasons were novel diagnoses, structured questionnaires cannot supplant a full medical history taken by a physician, as is also documented by the fact that all prospective donors had passed a structured questionnaire, yet almost half of the deferred donors were already identified as ineligible based on issues uncovered during history taking. The same-necessity of donor assessment by physicians-applies to the physical examination, ultrasound examination and interpretation of laboratory results in the context of both. We therefore advocate that the responsible task of unrelated stem cell donor evaluation should not be delegated to paramedical personnel.
In summary, stem cell donor exclusion rates differ from those of blood (component) donors. After careful eligibility assessment, more than 3% of referred donors cannot be cleared within an acceptable time window to donate any source of stem cells, and almost two times that many are ineligible for one or the other type of stem cell donation. The likelihood of a deferral increases with gender and age, as well as with the preferred stem cell source.
